Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2022

Open Access 01-12-2022 | Splenectomy | Case Report

Very severe immune thrombocytopenia following SARS-CoV-2 vaccination requiring splenectomy: a case report

Authors: Marc Weiner, Robert Rodriguez-Vigouroux, Stavroula Masouridi-Levrat, Kaveh Samii

Published in: Thrombosis Journal | Issue 1/2022

Login to get access

Abstract

Background

Some conventional vaccines have been recognized as a cause of secondary immune thrombocytopenia (ITP). According to recent publications, mRNA vaccines are probably associated with an increased risk of ITP.

Case presentation

Our patient developed severe ITP one week after the second dose of COVID-19 mRNA vaccine. Medical management was not effective, requiring splenectomy to obtain sustained remission.

Conclusion

Considering the temporality and immunological hypothesis, we consider the vaccine to be the trigger of this ITP. To our knowledge, our case is, to date, the most severe case of ITP reported following SARS-CoV-2 vaccination and could help for the therapeutic management of similar patients.
Literature
1.
Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16:620–32.CrossRef
2.
Rodeghiero F, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.CrossRef
3.
Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46:S2–14.CrossRef
4.
Palandri F, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years: Immune thrombocytopenia treatment over time. Am J Hematol. 2016;91:E267–72.CrossRef
5.
Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. 4. Haematologica. 2005;90:829-832.
6.
O’Leary ST, et al. The Risk of Immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics. 2012;129:248–55.CrossRef
7.
Yang X, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18:1469–72.CrossRef
8.
9.
Lee E, et al. Thrombocytopenia following pfizer and moderna SARS-CoV -2 vaccination. Am J Hematol. 2021;96:534–7.CrossRef
10.
Welsh KJ, Baumblatt J, Chege W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine adverse event reporting system (VAERS). Vaccine. 2021;39:3329–32.CrossRef
11.
Michel M. Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J Haematol. 2009;82:3–7.CrossRef
12.
Stirnemann J, et al. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2016;96:269–75.CrossRef
Metadata
Title
Very severe immune thrombocytopenia following SARS-CoV-2 vaccination requiring splenectomy: a case report
Authors
Marc Weiner
Robert Rodriguez-Vigouroux
Stavroula Masouridi-Levrat
Kaveh Samii
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2022
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-022-00404-z

Other articles of this Issue 1/2022

Thrombosis Journal 1/2022 Go to the issue

Case Report

Acute lower limb ischemia caused by vaccine-induced immune thrombotic thrombocytopenia: focus on perioperative considerations for 2 cases

Research

The efficacy of tranexamic acid treatment with different time and doses for traumatic brain injury: a systematic review and meta-analysis

Research

Prevalence and risk factor of post-operative lower extremities deep vein thrombosis in patients undergoing gynecologic surgery: a single-institute cross-sectional study

Correction

Correction to: D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and metanalysis

Research

Incidence of proximal deep vein thrombosis in medical critical care patients

Research

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits